Enable JavaScript to visit this website.
Skip directly to content

Pfizer enters a new collaboration in cardiovascular health with HLS Therapeutics Inc.

13/09/21

MONTREAL, QC – September 13, 2021 – Pfizer Inc. has recently expanded its engagement with cardiovascular health professionals as part of its collaboration with HLS Therapeutics Inc. The goal of this joint effort is to begin educating primary care physicians in Canada on a cardiovascular therapy marketed by HLS.

“We’re proud of our long-standing commitment to cardiovascular health, as well as our strong track record of successful collaboration with partner organizations in the biopharmaceutical industry,” says Cole C. Pinnow, President, Pfizer Canada. “We are excited to work with HLS to further this legacy and to continue to educate primary health care providers on the latest science related to cardiovascular disease.” 

About HLS Therapeutics Inc.

Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS’s focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS’s management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit: www.hlstherapeutics.com

About Pfizer Inc.

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com.

In addition, to learn more, please visit us on www.pfizer.com  and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

 

-30-

For further information:

Corporate Affairs Canada

1-866-9PFIZER (1-866-973-4937)

[email protected]